Pfizer Inc and
Adaptive Biotechnologies Corporation have entered into a translational
research collaboration to leverage next generation sequencing of the
adaptive immune system to advance Pfizer’s growing immuno-oncology
franchise. Under the terms of the agreement, Pfizer and Adaptive will
seek to combine drug development and platform technology biomarker
expertise to identify patients who may preferentially benefit from
immunotherapy.
Understanding
and reliably measuring each patient’s immune response to their cancer
before and after therapy is critical to defining the most appropriate
immunotherapy for that patient. Adaptive’s immunosequencing platform
quantitatively and reproducibly measures the patient’s immune-cell
repertoire, providing a powerful translational tool to accelerate
Pfizer’s immuno-oncology biomarker and drug development programs.
Adaptive Biotechnologies, the leading experts in profiling the immune
cell repertoire, will work with Pfizer to apply their proprietary
immunosequencing platform technology, bioinformatics capability, and
scientific expertise to advance Pfizer’s rapidly expanding
immuno-oncology pipeline.
